VIOLET: Variability of Daily Iodine Intake: The Effects of Intra- and Inter-individual Variability in Iodine Nutrition Studies

Sponsor
Swiss Federal Institute of Technology (Other)
Overall Status
Completed
CT.gov ID
NCT03731312
Collaborator
(none)
206
1
31.1
6.6

Study Details

Study Description

Brief Summary

Iodine status in populations is assessed using urinary iodine concentration (UIC) measured in spot urine samples. The iodine intake is classified as deficient, sufficient, or excessive iodine based on the median UIC (mUIC). However, this approach has limitations, as it does not quantify the prevalence of individuals with habitually deficient or excess iodine intakes. The EAR cut-point method has the potential to quantify prevalence of iodine deficiency and excess. However, little is known about the effects of the inter- and intra-individual variance of UIC.

The aim of the study is to quantify the intra-individual variability in dietary iodine intake. The overall goal is to estimate the prevalence of iodine deficiency and excess in the study population and propose sample size recommendations for future iodine nutrition population studies. The results will provide evidence guiding international recommendations for iodine nutrition studies.

Condition or Disease Intervention/Treatment Phase
  • Other: No intervention

Study Design

Study Type:
Observational
Actual Enrollment :
206 participants
Observational Model:
Ecologic or Community
Time Perspective:
Cross-Sectional
Official Title:
Variability of Daily Iodine Intake: The Effects of Intra- and Inter-individual Variability on Estimated Intake in Iodine Nutrition Studies
Actual Study Start Date :
Oct 1, 2018
Actual Primary Completion Date :
May 4, 2021
Actual Study Completion Date :
May 4, 2021

Arms and Interventions

Arm Intervention/Treatment
Study group

We will collect two repeated spot urine samples, a DBS sample and obtain weight in all 600 study participants. In a randomly selected subsample (n=200) a third repeat spot urine sample and one 24 h urine will additionally be collected.

Other: No intervention
This is an observational study and no interventions will be administered.

Outcome Measures

Primary Outcome Measures

  1. Estimated daily urinary iodine excretion [7 days]

    Estimated urinary iodine excretion (µg/day) will be obtained from urinary iodine concentration (UIC) and urinary creatinine concentration (UCC) measured in two repeat spot urine samples collected within 7 days

Secondary Outcome Measures

  1. Measured daily iodine excretion [1 day]

    Measured daily iodine excretion (µg/day) will be obtained from urinary iodine concentration (UIC) and urine volume in a 24 h urine collection

  2. Thyroid function test TSH [1 day]

    TSH concentration (mU/L) measured in dried blood spots

  3. Thyroid function test total T4 [1 day]

    Total T4 concentration (nmol/L) measured in dried blood spots

  4. Thyroid function test Tg [1 day]

    Tg concentration (µg/L) measured in dried blood spots

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 44 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Non-pregnant

  • Non-lactating

  • Non-smoking

  • Residence in Switzerland ≥12 months

  • Generally healthy

  • No family history of goiter

  • No exposure to iodine containing contrast agents during the last 12 months - Informed consent given

Exclusion Criteria:
  • Participant is not able to understand the study information or procedure, e.g. due to linguistic barriers

Contacts and Locations

Locations

Site City State Country Postal Code
1 ETH Zurich Zürich Switzerland 8092

Sponsors and Collaborators

  • Swiss Federal Institute of Technology

Investigators

  • Principal Investigator: Jessica Rigutto-Farebrother, PhD, ETH Zurich

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Swiss Federal Institute of Technology
ClinicalTrials.gov Identifier:
NCT03731312
Other Study ID Numbers:
  • VIOLET
First Posted:
Nov 6, 2018
Last Update Posted:
Sep 14, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Swiss Federal Institute of Technology

Study Results

No Results Posted as of Sep 14, 2021